Intraoperative Quantitative Measurements for Bradykinesia Evaluation during Deep Brain Stimulation Surgery Using Leap
Jingchao Wu1, Ningbo Yu2,3, Yang Yu4
1Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin 300350, China.
Parkinson'S Disease
|July 5, 2021
Summary
The Leap Motion Controller (LMC) accurately quantifies bradykinesia in Parkinson's disease (PD) patients during deep brain stimulation (DBS) surgery. This technology enhances intraoperative assessment of motor function, improving treatment efficacy for PD.
Area of Science:
- Neurology
- Biomedical Engineering
- Movement Disorders
Background:
- Deep brain stimulation (DBS) is highly effective for Parkinson's disease (PD).
- Intraoperative assessment of bradykinesia during DBS surgery is crucial for optimizing stimulation parameters.
- Current methods for assessing bradykinesia may lack precision.
Purpose of the Study:
- To evaluate the Leap Motion Controller (LMC) for quantifying bradykinesia in PD patients during DBS surgery.
- To enhance the accuracy of intraoperative bradykinesia assessment.
- To explore LMC's potential for objective motor function evaluation.
Main Methods:
- Seven idiopathic PD patients undergoing bilateral subthalamic nucleus DBS therapy were recruited.
- Participants performed finger tapping, hand opening/closing, and pronation/supination tasks pre- and intraoperatively.
- The Leap Motion Controller (LMC) and clinicians simultaneously monitored motor tasks.
Main Results:
- Key kinematic parameters showed differences between preoperative and intraoperative conditions.
- Average velocity and amplitude of pronation/supination tasks effectively isolated bradykinetic features.
- The LMC demonstrated promising results in evaluating hand and finger bradykinesia.
Conclusions:
- The Leap Motion Controller (LMC) offers a precise method for quantifying bradykinesia in Parkinson's disease (PD) patients during DBS surgery.
- LMC-derived kinematic parameters can serve as objective measures of the intraoperative motor state.
- This technology has the potential to refine DBS therapy for PD.


